Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Enlivex ( (ENLV) ) has provided an update.
On August 29, 2025, Enlivex Therapeutics Ltd. released its unaudited condensed consolidated financial statements for the periods ending June 30, 2025, and December 31, 2024. The report highlighted a decrease in total assets from $27.7 million at the end of 2024 to $22.6 million by mid-2025, alongside a net loss of $5.3 million for the first half of 2025. This financial update reflects ongoing challenges in managing operational costs and sustaining financial health, impacting the company’s market positioning and stakeholder confidence.
The most recent analyst rating on (ENLV) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Underperform.
Enlivex’s financial challenges, characterized by no revenue and ongoing cash burn, significantly impact its stock score. Technical indicators show neutral momentum, but the negative valuation metrics reflect ongoing financial difficulties. The absence of positive corporate events or earnings call data limits the potential for a higher score.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Therapeutics Ltd. is a company based in Israel, operating within the biotechnology industry. The company focuses on developing innovative therapies for life-threatening immune-related diseases, with a particular emphasis on cell therapy solutions.
Average Trading Volume: 514,719
Technical Sentiment Signal: Sell
Current Market Cap: $24.8M
Find detailed analytics on ENLV stock on TipRanks’ Stock Analysis page.